Morphic Holding announced a proposed underwritten public offering of its common stock. Morphic intends to use the net proceeds from the proposed offering, together with its existing cash, cash equivalents and marketable securities, to fund research, clinical trials and process development and manufacturing of Morphic’s product candidates, including MORF-057 and other programs generated from Morphic’s MInT Platform, working capital, capital expenditures and other general corporate purposes. Jefferies, TD Cowen, BMO Capital Markets, RBC Capital Markets and Wells Fargo Securities are acting as joint bookrunners for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MORF:
- Morphic Therapeutic Announces Pricing of $240.0 Million Public Offering
- Morphic Therapeutic Announces Proposed Public Offering
- Morphic price target raised to $106 from $83 at BMO Capital
- Morphic price target raised to $80 from $75 at RBC Capital
- Morphic price target raised to $80 from $67 at Wells Fargo